NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 2.2023: Featured Updates to the NCCN Guidelines

Ettinger, David S.; Wood, Douglas E.; Aisner, Dara L.; Akerley, Wallace; Bauman, Jessica R.; Bharat, Ankit; Bruno, Debora S.; Chang, Joe Y.; Chirieac, Lucian R.; DeCamp, Malcolm; Dilling, Thomas J.; Dowell, Jonathan; Durm, Gregory A.; Gettinger, Scott; Grotz, Travis E.; Gubens, Matthew A.; Hegde, Aparna; Lackner, Rudy P.; Lanuti, Michael; Lin, Jules; Loo, Billy W.; Lovly, Christine M.; Maldonado, Fabien; Massarelli, Erminia; Morgensztern, Daniel; Ng, Thomas; Otterson, Gregory A.; Patel, Sandip P.; Patil, Tejas; Polanco, Patricio M.; Riely, Gregory J.; Riess, Jonathan; Schild, Steven E.; Shapiro, Theresa A.; Singh, Aditi P.; Stevenson, James; Tam, Alda; Tanvetyanon, Tawee; Yanagawa, Jane; Yang, Stephen C.; Yau, Edwin; Gregory, Kristina M.; Hughes, Miranda

doi:10.6004/jnccn.2023.0020

Cited by 498

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 2.2023: Featured Updates to the NCCN Guidelines

Open access

Ettinger, David S., Wood, Douglas E., Aisner, Dara L., Akerley, Wallace, Bauman, Jessica R., Bharat, Ankit, Bruno, Debora S., Chang, Joe Y., Chirieac, Lucian R., DeCamp, Malcolm, Dilling, Thomas J., Dowell, Jonathan, Durm, Gregory A., Gettinger, Scott, Grotz, Travis E., Gubens, Matthew A., Hegde, Aparna, Lackner, Rudy P., Lanuti, Michael, Lin, Jules, Loo, Billy W., Lovly, Christine M., Maldonado, Fabien, Massarelli, Erminia, Morgensztern, Daniel, Ng, Thomas, Otterson, Gregory A., Patel, Sandip P., Patil, Tejas, Polanco, Patricio M., Riely, Gregory J., Riess, Jonathan, Schild, Steven E., Shapiro, Theresa A., Singh, Aditi P., Stevenson, James, Tam, Alda, Tanvetyanon, Tawee, Yanagawa, Jane, Yang, Stephen C., Yau, Edwin, Gregory, Kristina M., Hughes, Miranda·2023·Journal of the National Comprehensive Cancer Network

DOI 10.6004/jnccn.2023.0020

Open this paper in CoChat — free account

Abstract

The NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC) provide recommendations for management of disease in patients with NSCLC. These NCCN Guidelines Insights focus on neoadjuvant and adjuvant (also known as perioperative) systemic therapy options for eligible patients with resectable NSCLC.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.6004/jnccn.2023.0020

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

SEER Cancer Statistics Review, 1975-2003
Ries, L. A. G., Harkins, D., Krapcho, M. F., Mariotto, A. B., Miller, B., Feuer, E. J., Clegg, L. X., Eisner, M. P., Horner, M., Howlader, N., et al. (2006) · Digital Archive @ GSU · Cited by 11,403
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6385 · Cited by 3,713
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
Forde, P. M., Spicer, J., Lu, S., Provencio, M., Mitsudomi, T., Awad, M. M., Felip, E., Broderick, S. R., Brahmer, J. R., Swanson, S. J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2202170 · Cited by 2,825
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
Pignon, J.-P., Tribodet, H., Scagliotti, G. V., Douillard, J.-Y., Shepherd, F. A., Stephens, R. J., Dunant, A., Torri, V., Rosell, R., Seymour, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9030 · Cited by 2,642
Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater
Reck, M., Rodríguez–Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00149 · Cited by 1,670
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
Felip, E., Altorki, N., Zhou, C., Csőszi, T., Vynnychenko, I., Goloborodko, O., Luft, A., Akopov, A., Martinez-Marti, A., Kenmotsu, H., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02098-5 · Cited by 1,486
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
Mazieres, J., Drilon, A., Lusque, A., Mhanna, L., Cortot, A. B., Mezquita, L., Thai, A. A., Mascaux, C., Couraud, S., Veillon, R., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz167 · Cited by 1,354
Self-citation
A Randomized Trial Comparing Perioperative Chemotherapy and Surgery With Surgery Alone in Resectable Stage IIIA Non-Small-Cell Lung Cancer
Roth, J. A., Fossella, F., Komaki, R., Ryan, M. B., Putnam, J. B., Lee, J. S., Dhingra, H., De Caro, L., Chasen, M., McGavran, M., et al. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.9.673 · Cited by 1,111
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial.
Provencio, M., Nadal, E., Insa, A., García-Campelo, M. R., Casal-Rubio, J., Dómine, M., Majem, M., Rodríguez-Abreu, D., Martínez-Martí, A., De Castro Carpeño, J., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30453-8 · Cited by 841
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
O’Brien, M., Paz-Ares, L., Marreaud, S., Dafni, U., Oselin, K., Havel, L., Esteban, E., Isla, D., Martinez-Marti, A., Faehling, M., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00518-6 · Cited by 774

Show all 24 references

Appropriateness and Comprehensiveness of Using ChatGPT for Perioperative Patient Education in Thoracic Surgery in Different Language Contexts: Survey Study
Shao, C.-Y., Li, H., Liu, X.-L., Li, C., Yang, L.-Q., Zhang, Y.-J., Luo, J., & Zhao, J. (2023) · Interactive Journal of Medical Research · doi:10.2196/46900 · Cited by 49

See all 498

Authors: Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., DeCamp, M., Dilling, T. J., Dowell, J., Durm, G. A., Gettinger, S., Grotz, T. E., Gubens, M. A., Hegde, A., Lackner, R. P., Lanuti, M., Lin, J., Loo, B. W., Lovly, C. M., Maldonado, F., Massarelli, E., Morgensztern, D., Ng, T., Otterson, G. A., Patel, S. P., Patil, T., Polanco, P. M., Riely, G. J., Riess, J., Schild, S. E., Shapiro, T. A., Singh, A. P., Stevenson, J., Tam, A., Tanvetyanon, T., Yanagawa, J., Yang, S. C., Yau, E., Gregory, K. M., & Hughes, M.
Venue: Journal of the National Comprehensive Cancer Network
Publisher: Harborside Press, LLC
Published: 2023-04
Volume: 21
Issue: 4
Pages: 340-350
ISSN: 1540-1405 (ISSN-L)
1540-1413
DOI: 10.6004/jnccn.2023.0020
OpenAlex: W4362596712
Cited by: 498
References: 24
FWCI: 79.11
Type: journal article
Language: en
Open access: bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page: CoChat. (2026). Citation check: NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 2.2023: Featured Updates to the NCCN Guidelines. https://app.cochat.ai/papers/10.6004/jnccn.2023.0020
The paper: Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., DeCamp, M., Dilling, T. J., Dowell, J., Durm, G. A., Gettinger, S., Grotz, T. E., Gubens, M. A., Hegde, A., Lackner, R. P., Lanuti, M., . . . Hughes, M. (2023). NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 2.2023: Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network. https://doi.org/10.6004/jnccn.2023.0020

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 2.2023: Featured Updates to the NCCN Guidelines

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Self-check

Citations

Cites

Cited by

Metadata

Record

About these checks

How to cite

Data sources